Boehringer Aims To Block GSK's Triple COPD Inhaler, Citing Combo Rule

GSK's triple COPD combo needs Phase III trial using comparators with same active ingredients and applying factorial design, BI contends in citizen petition to US FDA.

lung illustration

More from Approval Standards

More from Pathways & Standards